论文部分内容阅读
目的 探讨肝硬化患者血清可溶性细胞间粘附分子1(sICAM -1)水平变化与肝细胞损伤的关系。方法 用酶联免疫吸附试验(ELISA)检测40例肝硬化患者和18名正常对照组血清sICAM -1水平。结果 肝硬化患者血清sICAM -1水平高于正常对照组,且肝功能ChildC级患者血清sICAM -1水平高于ChildB级和ChildA级患者 ;肝硬化患者血清sICAM -1水平与肝功能指标天门冬酸转氨酶水平呈正相关 (r=0.2754,P<0.05) ,与白蛋白水平呈负相关 (r= -0.4681,P<0.01)。结论 肝硬化患者血清sICAM -1水平增高与肝细胞损伤、肝功能障碍有关,血清sICAM -1水平监测可作为临床观察肝硬化患者病变活动的重要免疫学指标。
Objective To investigate the relationship between serum soluble intercellular adhesion molecule-1 (sICAM-1) level and hepatocellular injury in patients with liver cirrhosis. Methods Serum levels of sICAM-1 in 40 patients with cirrhosis and 18 normal controls were detected by enzyme linked immunosorbent assay (ELISA). Results The serum level of sICAM-1 in cirrhotic patients was higher than that in normal controls, and serum sICAM-1 levels in patients with liver function ChildC were higher than those in ChildB and ChildA patients. Serum levels of sICAM- (R = 0.2754, P <0.05), but negatively correlated with albumin (r = -0.4681, P <0.01). Conclusion The increase of serum sICAM-1 level in patients with cirrhosis is related to liver cell injury and liver dysfunction. The monitoring of serum sICAM-1 level may be used as an important immunological index to observe the pathological changes of patients with cirrhosis.